Narrow Results

The aim of our study was to investigate the effect of Patrinia scabra Bunge polysaccharide (PSB-P2) on cervical cancer cell (U14)-bearing mice. The tumor weight of mice treated with PSB-P2 (40, 80 mg/kg b.w.) was significantly lower than that of the control group and serum lactate dehydrogenase (LDH) activity was decreased, while serum alkaline phosphatase (AKP) level was only changed slightly. Meanwhile, the number of apoptotic tumor cells was significantly increased in the mice by the treatment of PSB-P2 (40, 80 mg/kg b.w.). At the same time, cell cycle analysis showed the accumulation of tumor cells in the G0/G1 phase and a relative decrease in the S phase. On the other hand, using the reverse transcription-polymerase chain reaction (RT-PCR) assay, PSB-P2 (40, 80 mg/kg b.w.) showed the up-regulation of p53 and Bax, and significant inhibition of Bcl-2 in tumor tissues. It suggests a possible mechanism of the inhibitory effect of PSB-P2 on tumor growth.

AUSTRALIA – Chronic pain research delves into the brain

KOREA – STC life, Ltd. successfully treats stroke patients at Stem Cell Research Treatment Center

MALAYSIA – Indigenous people ‘at graver risk’ of neglected diseases

SINGAPORE – A*STAR scientists create stem cells from a drop of blood

THE PHILIPPINES – ‘Too many exotic species’ in Philippine greening plan

AFRICA – The parasite that escaped out of Africa

CANADA – Genome British Columbia researchers closing in on chlamydia vaccine

EUROPE – Teesside University pioneering life-saving research

EUROPE – Inactivated polio vaccines broadly available for the world's children in the drive toward polio eradication

EUROPE – Vitamin D deficiency may compromise immune function

EUROPE – Inflammation mobilizes tumor cells

NEPAL – Animal-borne parasites plague Nepal

UNITED STATES – Zebrafish discovery may shed light on human kidney function

UNITED STATES – Nanoparticles and magnetic fields train immune cells to fight cancer in mice

UNITED STATES – Building heart tissue that beats

UNITED STATES – Immunology researchers uncover pathways that direct immune system to turn ‘on’ or ‘off’

UNITED STATES – How diabetes drugs may work against cancer

UNITED STATES – Study reveals how a protein common in cancers jumps anti-tumor mechanisms

Photodynamic therapy (PDT) has been a potential therapeutic method for the treatment of various cancers, with photosensitizer being the key component in photodynamic therapy. In this paper, we prepared a photosensitizer 3-(1-hydroxylethyl)-3-devinyl-13¹-(dicyanomethylene) pyropheophorbide-a methyl ester (HDCPPa), based on chlorophyll pyropheophorbide-a according to the previous report, and systematically investigated the fluorescence emission spectrum and ultraviolet absorption spectrum HDCPPa has long absorption in the near-infrared spectral region (around 695 nm). The excitation wavelength and the emission wavelength were 415 nm and 699 nm respectively in dichloromethane, ¹O₂ quantum yield was 63.5%. HDCPPa also had high stability in PBS solution, DMEM cell culture medium and normal saline (NS) in vitro. After irradiation by the light of 675 nm (10 J.cm${}^{-2}$) for 70 min the degradation rate of HDCPPa was 12.5%, which indicated that the target compound showed high stability under light. The in vitrophotodynamic therapy activities against HeLa cells were also studied, which showed that HDCPPa had extremely low dark toxicity but great phototoxicity, and the cell viability is lower than 10% under the light irradiation of 675 nm (10 J.cm${}^{-2}$). Moreover, HDCPPa can quickly enter the cell after being incubated with HeLa cells in less than 30 min. We also evaluated the mechanism of the photochemical reaction, which had proved that Type II is primarily responsible for the cell death. Therefore HDCPPa could serve as a very promising photosensitizer for photodynamic therapy.